Silo Pharma Inc. (NASDAQ: SILO) has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application covering its lead intranasal therapeutic, SPC-15, aimed at treating post-traumatic stress disorder (PTSD). The invention, titled "Compositions and Methods for the Prevention of Stress-Induced Fear, Depressive-Like and Anxiety-Like Behavior," includes both composition and method claims for the company's proprietary approach to preventing or delaying stress-induced behavioral responses. This allowance signifies that the USPTO has completed its examination and determined that the application meets the requirements for patentability, with the patent expected to be granted shortly.
The significance of this patent allowance lies in its potential to bolster Silo Pharma's competitive position in the neuropsychiatric therapeutic space. PTSD is a debilitating condition that affects millions worldwide, and current treatment options often have limited efficacy and significant side effects. SPC-15, with its intranasal delivery and novel mechanism, could offer a more targeted and convenient approach. The patent protection in the U.S. is a critical component of Silo's strategy as it advances SPC-15 through development, adding to its growing portfolio of issued and allowed patents. A corresponding patent was issued by the Japan Patent Office earlier this year, indicating global recognition of the innovation.
"The U.S. patent protection is an important component of our strategy as we advance SPC-15 development for PTSD," said a company spokesperson. "This allowance adds to our biopharmaceutical intellectual property portfolio of issued and allowed patents, reinforcing our commitment to addressing underserved conditions."
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company focused on underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system diseases. Its portfolio includes SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. Research is conducted in collaboration with leading universities and laboratories.
The patent allowance comes at a time when mental health awareness is rising, and the need for innovative PTSD treatments is more urgent than ever. According to the U.S. Department of Veterans Affairs, about 6% of the U.S. population will experience PTSD at some point in their lives, with certain groups, such as veterans, at higher risk. Existing therapies, including selective serotonin reuptake inhibitors and psychotherapy, are not universally effective, underscoring the demand for new options. SPC-15's potential to prevent or delay stress-induced fear and anxiety could represent a paradigm shift in how PTSD is managed, particularly if it proves effective in clinical trials.
For investors, the patent allowance reduces regulatory risk and enhances the value of Silo's intellectual property. It also provides a foundation for potential partnerships or licensing deals with larger pharmaceutical companies. The company's dual focus on biopharmaceuticals and cryptocurrency treasury adds a layer of diversification, though the latter is not detailed in this announcement.
To view the full press release, visit https://ibn.fm/Hh4Z6. For more information about Silo Pharma, visit silopharma.com. The latest news and updates relating to SILO are available in the company's newsroom at https://ibn.fm/SILO.
